Take a look at this month’s industry headlines including FDA warnings over hepatitis C drugs in patients with liver injury, a new infectious diseases strategy for the UK and priority review for Merck’s Ebola vaccine.
B. Joanne Power gives us a summary of the conference highlights from BioMalPar XV, including new strategies for vector control and new insights into the malaria parasite.
Take a look at this month’s industry headlines including an FDA approval for Zebraxa, new funding for chikungunya vaccine clinical…
Take a look at this month’s industry headlines including US FDA approvals for Mavyret (hepatitis C) and Dengvaxia, a rejection for Contepo and profits for Gilead Sciences.
Take a look behind the scenes of a recent Future Virology review, entitled: ‘Comparative host genomics: Has recent human evolution affected our immune defense against hepatitis C virus?’, as we ask the authors about the importance of the IFNL4 gene and the work that’s still to be done in the field.
Take a look behind the scenes of a recent Future Virology review entitled ‘An update on the management of hepatitis C virus and human immunodeficiency virus coinfection’, as we ask the authors about their inspiration and the future of this field.
Find out more about the headlines from the Conference on Retroviruses and Opportunistic Infections 2019 (CROI) in our round-up of conference news.
We take a look back at some of the largest outbreaks of 2018 and their impacts, read the full story to learn more.
The largest population study of hepatitis C in Africa has discovered three new strains of the virus with unknown susceptibility to currently used antiviral treatments.
During the current opioid crisis, only one-third of youths diagnosed with opioid use disorder were tested for hepatitis C, according to the results of a large national sample presented at IDWeek.
